MX2020013103A - Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. - Google Patents
Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.Info
- Publication number
- MX2020013103A MX2020013103A MX2020013103A MX2020013103A MX2020013103A MX 2020013103 A MX2020013103 A MX 2020013103A MX 2020013103 A MX2020013103 A MX 2020013103A MX 2020013103 A MX2020013103 A MX 2020013103A MX 2020013103 A MX2020013103 A MX 2020013103A
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- treatment
- methods
- leukemia relapse
- relapse
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
La presente invención se refiere al uso de una proteína CD24 para prevenir o tratar la recaída de un cáncer en un sujeto. La presente invención también se refiere al uso de una proteína CD24 para reducir la actividad de células madre cancerosas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862680218P | 2018-06-04 | 2018-06-04 | |
US201862739742P | 2018-10-01 | 2018-10-01 | |
US201862739719P | 2018-10-01 | 2018-10-01 | |
PCT/US2019/035205 WO2019236474A1 (en) | 2018-06-04 | 2019-06-03 | Methods of use of cd24 for the prevention and treatment of leukemia relapse |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013103A true MX2020013103A (es) | 2021-05-12 |
Family
ID=68770596
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013100A MX2020013100A (es) | 2018-06-04 | 2019-06-03 | Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. |
MX2020013103A MX2020013103A (es) | 2018-06-04 | 2019-06-03 | Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013100A MX2020013100A (es) | 2018-06-04 | 2019-06-03 | Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20210228680A1 (es) |
EP (2) | EP3802583A4 (es) |
JP (2) | JP2021527066A (es) |
KR (2) | KR20210018294A (es) |
CN (2) | CN112512640A (es) |
AU (2) | AU2019282530A1 (es) |
BR (2) | BR112020024683A2 (es) |
CA (2) | CA3102372A1 (es) |
CL (2) | CL2020003168A1 (es) |
IL (2) | IL279205A (es) |
MA (2) | MA52810A (es) |
MX (2) | MX2020013100A (es) |
SG (2) | SG11202011963UA (es) |
TW (2) | TW202015753A (es) |
WO (2) | WO2019236472A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020013100A (es) * | 2018-06-04 | 2021-02-17 | Oncoimmune Inc | Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. |
US20230108492A1 (en) * | 2020-02-10 | 2023-04-06 | Oncoimmune, Inc. | Methods of use of soluble cd24 for treating viral pneumonia |
WO2023205742A1 (en) * | 2022-04-20 | 2023-10-26 | OncoC4, Inc. | Mutant cd24 proteins and uses thereof for prophylaxis and treatment of cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
WO2009063461A1 (en) | 2007-11-14 | 2009-05-22 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using anti cd24 antibodies |
US20130231464A1 (en) * | 2010-04-28 | 2013-09-05 | Oncolmmune, Inc. | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
PL3260128T3 (pl) * | 2010-04-28 | 2021-02-08 | Oncoimmune, Inc. | Zastosowanie medyczne rozpuszczalnego CD24 |
CN102250828B (zh) * | 2010-11-10 | 2014-11-05 | 北京大学 | Cd24及cd24抗体的新用途 |
WO2013158959A1 (en) * | 2012-04-19 | 2013-10-24 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of graft-versus-host disease |
WO2016073704A1 (en) | 2014-11-06 | 2016-05-12 | Children's Research Institute, Children's National Medical Center | Immunotherapeutics for cancer and autoimmune diseases |
CN107531772B (zh) * | 2015-05-07 | 2021-09-21 | 肿瘤免疫股份有限公司 | Cd24用于降低低密度脂蛋白胆固醇水平的用途 |
US10799558B2 (en) * | 2016-02-02 | 2020-10-13 | Oncoimmune, Inc. | Use of CD24 proteins for treating leptin-deficient conditions |
MX2020013100A (es) * | 2018-06-04 | 2021-02-17 | Oncoimmune Inc | Metodos de uso de cd24 para la prevencion y tratamiento de enfermedad de injerto contra hospedero y mucositis. |
WO2021142336A1 (en) * | 2020-01-08 | 2021-07-15 | Puretech Lyt, Inc. | Vesicle compositions for oral delivery |
-
2019
- 2019-06-03 MX MX2020013100A patent/MX2020013100A/es unknown
- 2019-06-03 SG SG11202011963UA patent/SG11202011963UA/en unknown
- 2019-06-03 CA CA3102372A patent/CA3102372A1/en active Pending
- 2019-06-03 US US15/734,961 patent/US20210228680A1/en active Pending
- 2019-06-03 TW TW108119240A patent/TW202015753A/zh unknown
- 2019-06-03 JP JP2020568311A patent/JP2021527066A/ja active Pending
- 2019-06-03 EP EP19815874.3A patent/EP3802583A4/en active Pending
- 2019-06-03 BR BR112020024683-2A patent/BR112020024683A2/pt not_active Application Discontinuation
- 2019-06-03 JP JP2020567863A patent/JP2021527056A/ja active Pending
- 2019-06-03 WO PCT/US2019/035200 patent/WO2019236472A1/en unknown
- 2019-06-03 EP EP19815487.4A patent/EP3801773A4/en active Pending
- 2019-06-03 SG SG11202011964SA patent/SG11202011964SA/en unknown
- 2019-06-03 MA MA052810A patent/MA52810A/fr unknown
- 2019-06-03 CN CN201980050232.9A patent/CN112512640A/zh active Pending
- 2019-06-03 US US15/734,957 patent/US11911441B2/en active Active
- 2019-06-03 WO PCT/US2019/035205 patent/WO2019236474A1/en unknown
- 2019-06-03 BR BR112020024659-0A patent/BR112020024659A2/pt not_active Application Discontinuation
- 2019-06-03 CN CN201980049870.9A patent/CN112752766A/zh active Pending
- 2019-06-03 AU AU2019282530A patent/AU2019282530A1/en not_active Abandoned
- 2019-06-03 TW TW108119239A patent/TW202012015A/zh unknown
- 2019-06-03 AU AU2019282044A patent/AU2019282044A1/en not_active Abandoned
- 2019-06-03 KR KR1020207035971A patent/KR20210018294A/ko unknown
- 2019-06-03 MA MA052811A patent/MA52811A/fr unknown
- 2019-06-03 KR KR1020207036790A patent/KR20210021317A/ko unknown
- 2019-06-03 CA CA3102374A patent/CA3102374A1/en not_active Abandoned
- 2019-06-03 MX MX2020013103A patent/MX2020013103A/es unknown
-
2020
- 2020-12-03 IL IL279205A patent/IL279205A/en unknown
- 2020-12-03 IL IL279204A patent/IL279204A/en unknown
- 2020-12-04 CL CL2020003168A patent/CL2020003168A1/es unknown
- 2020-12-04 CL CL2020003169A patent/CL2020003169A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN112752766A (zh) | 2021-05-04 |
SG11202011964SA (en) | 2020-12-30 |
IL279205A (en) | 2021-01-31 |
EP3802583A4 (en) | 2022-03-16 |
JP2021527056A (ja) | 2021-10-11 |
CA3102374A1 (en) | 2019-12-12 |
EP3801773A4 (en) | 2022-03-16 |
KR20210021317A (ko) | 2021-02-25 |
EP3802583A1 (en) | 2021-04-14 |
US20210228680A1 (en) | 2021-07-29 |
MA52811A (fr) | 2022-03-16 |
JP2021527066A (ja) | 2021-10-11 |
MX2020013100A (es) | 2021-02-17 |
WO2019236472A1 (en) | 2019-12-12 |
MA52810A (fr) | 2021-04-14 |
WO2019236474A1 (en) | 2019-12-12 |
CL2020003168A1 (es) | 2021-06-11 |
TW202015753A (zh) | 2020-05-01 |
US20210268061A1 (en) | 2021-09-02 |
BR112020024659A2 (pt) | 2021-03-09 |
CN112512640A (zh) | 2021-03-16 |
US11911441B2 (en) | 2024-02-27 |
CA3102372A1 (en) | 2019-12-12 |
TW202012015A (zh) | 2020-04-01 |
KR20210018294A (ko) | 2021-02-17 |
IL279204A (en) | 2021-01-31 |
AU2019282044A1 (en) | 2021-01-07 |
AU2019282530A1 (en) | 2021-01-07 |
CL2020003169A1 (es) | 2021-06-11 |
EP3801773A1 (en) | 2021-04-14 |
SG11202011963UA (en) | 2020-12-30 |
BR112020024683A2 (pt) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021007790A (es) | Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
WO2017096309A8 (en) | Methods of treatment of malignancies | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2019011858A (es) | Metodos para tratar el cancer con anticuerpos dirigidos a ps con agentes inmunooncologicos. | |
MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
MY185579A (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
MX2017011834A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
MX2020013103A (es) | Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia. | |
MX2018006531A (es) | Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. | |
MX2021005761A (es) | Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados. | |
MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
PH12019500758A1 (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
WO2018208954A3 (en) | Peptidomimetic macrocycles and uses thereof | |
MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. |